Cornea · 2011
Histologic findings of bevacizumab-treated human conjunctiva in Stevens-Johnson syndrome.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uy Harvey S, Yu Ellen N, Sua Alex S
Аннотация
PURPOSE: To present the histopathologic findings of the conjunctiva of a patient with Stevens-Johnson syndrome (SJS)-associated ocular surface neovascularization (OSN) after topical bevacizumab (TB) treatment.
METHODS: A 40-year-old man with SJS and OSN received topical bevacizumab (25 mg/mL) for 12 months in 1 eye in addition to previously bilaterally administered tobramycin/dexamethasone eye drops. He subsequently underwent bilateral release of symblephara to relieve diplopia. Conjunctival samples from both eyes were obtained for histopathologic study.
RESULTS: The TB-untreated conjunctiva manifested marked stromal vascularization (approximately 4-5 blood vessels per high-power field) and perivascular mononuclear inflammatory cells. The TB-treated eye manifested with markedly less stromal vascularization (approximately 1-2 vessels per high-power field) in the conjunctiva and absence of perivascular inflammatory cells.
CONCLUSIONS: These histopathologic findings provide evidence that TB penetrates the ocular surface, induces regression of OSN, and possibly moderates ocular inflammation. TB may be a useful additional treatment for OSN among patients with SJS.
METHODS: A 40-year-old man with SJS and OSN received topical bevacizumab (25 mg/mL) for 12 months in 1 eye in addition to previously bilaterally administered tobramycin/dexamethasone eye drops. He subsequently underwent bilateral release of symblephara to relieve diplopia. Conjunctival samples from both eyes were obtained for histopathologic study.
RESULTS: The TB-untreated conjunctiva manifested marked stromal vascularization (approximately 4-5 blood vessels per high-power field) and perivascular mononuclear inflammatory cells. The TB-treated eye manifested with markedly less stromal vascularization (approximately 1-2 vessels per high-power field) in the conjunctiva and absence of perivascular inflammatory cells.
CONCLUSIONS: These histopathologic findings provide evidence that TB penetrates the ocular surface, induces regression of OSN, and possibly moderates ocular inflammation. TB may be a useful additional treatment for OSN among patients with SJS.